New schizophrenia drug candidate TAK-063 begins safety testing
NCT ID NCT01879722
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of multiple doses of TAK-063 in 77 participants, including people with stable schizophrenia and healthy Japanese volunteers. Researchers monitored side effects, lab results, and vital signs over 7 days. The study does not aim to treat schizophrenia but to gather initial safety data for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-063
- What this could lead to
- If successful, this could pave the way for larger studies to see if TAK-063 helps control schizophrenia symptoms.
- What could go wrong
- This is a very early Phase 1 trial focused only on safety, not on whether the drug works. The drug may cause side effects or fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Glendale, California, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?